NemaGen Discoveries is an early phase biotech company focused on advancing therapies for patients suffering from allergic inflammation and mast cell-related diseases.
NemaGen's novel technologies were developed by investigating the body's natural ability to prevent unwanted inflammation following parasitic infections. By taking this unique approach NemaGen has pioneered new therapeutic strategies to help patients suffering from diverse inflammatory diseases.
NemaGen's exciting findings have defined a previously unappreciated neuropeptide pathway that prevents unwanted lung inflammation. These studies were recently published in Nature Immunology.